Literature DB >> 21205828

Cullin-4A·DNA damage-binding protein 1 E3 ligase complex targets tumor suppressor RASSF1A for degradation during mitosis.

Lingyan Jiang1, Rong Rong, M Saeed Sheikh, Ying Huang.   

Abstract

Tumor suppressor RASSF1A (RAS association domain family 1, isoform A) is known to play an important role in regulation of mitosis; however, little is known about how RASSF1A is regulated during the mitotic phase of the cell cycle. In the present study, we have identified Cullin-4A (CUL4A) as a novel E3 ligase for RASSF1A. Our results demonstrate that DNA damage-binding protein 1 (DDB1) functions as a substrate adaptor that directly interacts with RASSF1A and bridges RASSF1A to the CUL4A E3 ligase complex. Depletion of DDB1 also diminishes intracellular interactions between RASSF1A and CUL4A. Our results also show that RASSF1A interacts with DDB1 via a region containing amino acids 165-200, and deletion of this region abolishes RASSF1A and DDB1 interactions. We have found that CUL4A depletion results in increased levels of RASSF1A protein due to increased half-life; whereas overexpression of CUL4A and DDB1 markedly enhances RASSF1A protein ubiquitination resulting in reduced RASSF1A levels. We further show that CUL4A-mediated RASSF1A degradation occurs during mitosis, and depletion of CUL4A markedly reverses mitotic-phase-stimulated RASSF1A degradation. We also note that overexpression of CUL4A antagonizes the ability of RASSF1A to induce M-phase cell cycle arrest. Thus, our present study demonstrates that the CUL4A·DDB1 E3 complex is important for regulation of RASSF1A during mitosis, and it may contribute to inactivation of RASSF1A and promoting cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205828      PMCID: PMC3044953          DOI: 10.1074/jbc.M110.186494

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.

Authors:  Mei Y Yu; Joanna H M Tong; Paul K S Chan; Tin L Lee; Michael W Y Chan; Anthony W H Chan; Kwok W Lo; Kai F To
Journal:  Int J Cancer       Date:  2003-06-10       Impact factor: 7.396

2.  Triggering ubiquitination of a CDK inhibitor at origins of DNA replication.

Authors:  L Furstenthal; C Swanson; B K Kaiser; A G Eldridge; P K Jackson
Journal:  Nat Cell Biol       Date:  2001-08       Impact factor: 28.824

3.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.

Authors:  D G Burbee; E Forgacs; S Zöchbauer-Müller; L Shivakumar; K Fong; B Gao; D Randle; M Kondo; A Virmani; S Bader; Y Sekido; F Latif; S Milchgrub; S Toyooka; A F Gazdar; M I Lerman; E Zabarovsky; M White; J D Minna
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

4.  TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Authors:  Kohichiroh Yasui; Shigeki Arii; Chen Zhao; Issei Imoto; Masakazu Ueda; Hisaki Nagai; Mitsuru Emi; Johji Inazawa
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

5.  The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.

Authors:  Latha Shivakumar; John Minna; Toshiyuki Sakamaki; Richard Pestell; Michael A White
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

6.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.

Authors:  Michael W Y Chan; Lung W Chan; Nelson L S Tang; Kwok Wai Lo; Joanna H M Tong; Anthony W H Chan; Ho Y Cheung; Wai S Wong; Peter S F Chan; Fernand M M Lai; Ka Fai To
Journal:  Int J Cancer       Date:  2003-05-01       Impact factor: 7.396

7.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors.

Authors:  Michael L Whitfield; Gavin Sherlock; Alok J Saldanha; John I Murray; Catherine A Ball; Karen E Alexander; John C Matese; Charles M Perou; Myra M Hurt; Patrick O Brown; David Botstein
Journal:  Mol Biol Cell       Date:  2002-06       Impact factor: 4.138

8.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.

Authors:  Yoshio Tomizawa; Takashi Kohno; Haruhiko Kondo; Ayaka Otsuka; Michiho Nishioka; Toshiro Niki; Tesshi Yamada; Arafumi Maeshima; Kimio Yoshimura; Ryusei Saito; John D Minna; Jun Yokota
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

9.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells.

Authors:  Igor Kuzmin; John W Gillespie; Alexei Protopopov; Laura Geil; Koen Dreijerink; Youfeng Yang; Cathy D Vocke; Fuh-Mei Duh; Eugene Zabarovsky; John D Minna; Johng S Rhim; Michael R Emmert-Buck; W Marston Linehan; Michael I Lerman
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.

Authors:  A Agathanggelou; S Honorio; D P Macartney; A Martinez; A Dallol; J Rader; P Fullwood; A Chauhan; R Walker; J A Shaw; S Hosoe; M I Lerman; J D Minna; E R Maher; F Latif
Journal:  Oncogene       Date:  2001-03-22       Impact factor: 9.867

View more
  19 in total

1.  Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.

Authors:  Guang Lu; Juan Yi; Andrea Gubas; Ya-Ting Wang; Yihua Wu; Yi Ren; Man Wu; Yin Shi; Chenxi Ouyang; Hayden Weng Siong Tan; Tianru Wang; Liming Wang; Nai-Di Yang; Shuo Deng; Dajing Xia; Ruey-Hwa Chen; Sharon A Tooze; Han-Ming Shen
Journal:  Autophagy       Date:  2019-03-30       Impact factor: 16.016

2.  Resistance to anti-microtubule drug-induced cell death is determined by regulation of BimEL expression.

Authors:  Weimei Ruan; Gireedhar Venkatachalam; Radoslaw Mikolaj Sobota; Liyan Chen; Loo Chien Wang; Alena Jacobson; Kathirvel Paramasivam; Uttam Surana
Journal:  Oncogene       Date:  2019-02-15       Impact factor: 9.867

3.  CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation.

Authors:  Yangyang Xu; Yunshan Wang; Guangxin Ma; Qin Wang; Guangwei Wei
Journal:  J Neurooncol       Date:  2014-01-14       Impact factor: 4.130

Review 4.  Distinct and overlapping functions of the cullin E3 ligase scaffolding proteins CUL4A and CUL4B.

Authors:  Jeffrey Hannah; Pengbo Zhou
Journal:  Gene       Date:  2015-09-03       Impact factor: 3.688

5.  Regulation of APC/CCdc20 activity by RASSF1A-APC/CCdc20 circuitry.

Authors:  C Chow; N Wong; M Pagano; S W-M Lun; K-I Nakayama; K Nakayama; K-W Lo
Journal:  Oncogene       Date:  2011-08-29       Impact factor: 9.867

6.  RASSF1 Polymorphisms in Cancer.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Shairaz Baksh
Journal:  Mol Biol Int       Date:  2012-05-31

7.  The cellular functions of RASSF1A and its inactivation in prostate cancer.

Authors:  Karishma S Amin; Partha P Banerjee
Journal:  J Carcinog       Date:  2012-02-17

8.  Pathogenic Role of the CRL4 Ubiquitin Ligase in Human Disease.

Authors:  Jennifer Lee; Pengbo Zhou
Journal:  Front Oncol       Date:  2012-03-06       Impact factor: 6.244

Review 9.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

10.  Phosphorylation and ubiquitination-dependent degradation of CABIN1 releases p53 for transactivation upon genotoxic stress.

Authors:  Soo-Youn Choi; Hyonchol Jang; Jae-Seok Roe; Seong-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Nucleic Acids Res       Date:  2013-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.